Epoetin Beta and C‐Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease

BACKGROUND: In patients with chronic heart failure and chronic kidney disease, correction of anemia with erythropoietin‐stimulating agents targeting normal hemoglobin levels is associated with an increased risk of cardiovascular morbidity and mortality. Emerging data suggest a direct effect of eryth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Eisenga, Michele F., Emans, Mireille E., van der Putten, Karien, Cramer, Maarten J., Diepenbroek, Adry, Velthuis, Birgitta K., Doevendans, Pieter A., Verhaar, Marianne C., Joles, Jaap A., Bakker, Stephan J. L., Nolte, Ilja M., Braam, Branko, Gaillard, Carlo A. J. M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6759901/
https://ncbi.nlm.nih.gov/pubmed/31423921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.011130
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados